Aligos Therapeutics
ALGS
38 hedge funds and large institutions have $25.3M invested in Aligos Therapeutics in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 15 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.11% less ownership
Funds ownership: 2.78% → 2.67% (-0.11%)
17% less capital invested
Capital invested by funds: $30.4M → $25.3M (-$5.13M)
27% less funds holding
Funds holding: 52 → 38 (-14)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
93% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.15M |
| 2 |
NM
Newtyn Management
New York
|
+$504K |
| 3 |
Millennium Management
New York
|
+$39.5K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$33.3K |
| 5 |
NYLIM
New York Life Investment Management
New York
|
+$30K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$2.15M |
| 2 |
BlackRock
New York
|
-$212K |
| 3 |
Renaissance Technologies
New York
|
-$200K |
| 4 |
Rockefeller Capital Management
New York
|
-$85K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$77.1K |
ALGS Hedge Fund Activity: Q4 2022 in Review
38 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aligos Therapeutics (ALGS) for Q4 2022, worth a combined $25.3M — down 17% from $30.4M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ALGS and 1 opened new positions — a net loss of 14 holders — while 13 trimmed existing stakes and 9 added.
The largest buyer was Tang Capital Management, adding an estimated $1.15M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $2.15M sold.
- 38 institutional investors held Aligos Therapeutics (ALGS) as of Q4 2022, down from 52 in Q3 2022.
- Funds reported $25.3M of Aligos Therapeutics stock for Q4 2022, down 17% quarter-over-quarter.
- 1 fund opened new Aligos Therapeutics positions in Q4 2022 and 15 closed out, a net change of -14 holders.
- The largest Aligos Therapeutics buyer in Q4 2022 was Tang Capital Management, an estimated $1.15M added.
- The largest Aligos Therapeutics seller in Q4 2022 was Novo Holdings A/S, an estimated $2.15M sold.
Based on aggregated 13F filings for Q4 2022.